Basit öğe kaydını göster

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma

dc.contributor.authorDi Bartolomeo, M.
dc.contributor.authorMandala, M.
dc.contributor.authorMuro, K.
dc.contributor.authorVan Cutsem, E.
dc.contributor.authorKobie, J.
dc.contributor.authorCristescu, R.
dc.contributor.authorAurora-Garg, D.
dc.contributor.authorLu, J.
dc.contributor.authorShih, C-S
dc.contributor.authorAdelberg, D.
dc.contributor.authorCao, Z. A.
dc.contributor.authorFuchs, C. S.
dc.contributor.authorShitara, K.
dc.contributor.authorÖZGÜROĞLU, Mustafa
dc.contributor.authorBang, Y-J
dc.contributor.authorRyu, M-H
dc.contributor.authorCaglevic, C.
dc.contributor.authorChung, H. C.
dc.date.accessioned2021-12-10T09:58:55Z
dc.date.available2021-12-10T09:58:55Z
dc.date.issued2021
dc.identifier.citationShitara K., ÖZGÜROĞLU M., Bang Y., Di Bartolomeo M., Mandala M., Ryu M., Caglevic C., Chung H. C. , Muro K., Van Cutsem E., et al., "Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma", ANNALS OF ONCOLOGY, cilt.32, sa.9, ss.1127-1136, 2021
dc.identifier.issn0923-7534
dc.identifier.otherav_2049990f-daa5-40d7-a024-1f3c5cf3e20a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/168922
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2021.05.803
dc.description.abstractBackground: In the phase III KEYNOTE-061 trial (NCT02370498), pembrolizumab did not significantly improve overall survival versus paclitaxel as second-line therapy for gastric/gastroesophageal junction (GEJ) adenocarcinoma with programmed death-ligand 1 (PD-L1) combined positive score (CPS) >= 1 tumors. The association of tissue tumor mutational burden (tTMB) status and clinical outcomes was determined, including the relationship with CPS and microsatellite instability-high (MSI-H) status.
dc.language.isoeng
dc.subjectOncology
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectHealth Sciences
dc.titleMolecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
dc.typeMakale
dc.relation.journalANNALS OF ONCOLOGY
dc.contributor.departmentNatl Canc Ctr Hosp East , ,
dc.identifier.volume32
dc.identifier.issue9
dc.identifier.startpage1127
dc.identifier.endpage1136
dc.contributor.firstauthorID2718174


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster